为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验，建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?)，感谢您选择我们！
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| E407789-1ml |
1ml |
现货  |
|
| 英文别名 | 2-Propanol, 2-methyl-1-[[4-[6-(trifluoromethyl)-2-pyridinyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]amino]-1,3,5-triazin-2-yl]amino]- |
|---|---|
| 规格或纯度 | 10mM in DMSO |
| 英文名称 | Enasidenib (AG-221) |
| 生化机理 | Enasidenib (AG-221) is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzyme. |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
Information Enasidenib (AG-221) Enasidenib (AG-221) is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzyme . The compound has been demonstrated to reduce 2-HG levels by >90% and reverse histone and deoxyribonucleic acid (DNA) hypermethylation in vitro, and to induce differentiation in leukemia cell models. In vivo AG-221 is able to potently reduce 2HG found in the bone marrow, plasma and urine of engrafted mice. Treatment also induced a dose dependent, statistically significant, survival benefit. A proliferative burst of the human specific CD45+ blast cells is followed by cellular differentiation as measured by the expression of CD11b, CD14 and CD15 and cell morphology after AG-221 treatment. AG-221 treatment also restores megakaryocyte-erythroid progenitor (MEP) differentiation that is suppressed by mutant IDH2 expression and reverses the effects of mutant IDH2 on DNA methylation in mutant stem/progenitor cells. Clinical trials combining IDH2 inhibitors with other targeted AML therapies are warranted in order to increase therapeutic efficacy. cell lines： Concentrations： Incubation Time： Powder Purity:≥99% |
| Canonical SMILES | CC(C)(O)CNC1=NC(=NC(=N1)NC2=CC=NC(=C2)C(F)(F)F)C3=NC(=CC=C3)C(F)(F)F |
|---|---|
| 分子量 | 473.38 |
输入批号以搜索COA:
首页
400-620-6333
危险品化学品经营许可证（带存储）